Codexis (CDXS) Aktie Kurs
Codexis Kurs
Under de senaste 19 åren växte Codexis intäkterna med 9,7 % årligen och nådde 70,39 M USD. För Codexis är nettovinstmarginal på −62,5 % ned jämfört med −20,3 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Codexis är 5,00 USD, cirka över kursen med 274,5 %. Av 13 analytiker ger 10 köpråd — den samlade bedömningen är Köp.
Codexis aktiekurs
Codexis affärsmodell och aktieanalys
Vanliga frågor om Codexis-aktien
The business model of Codexis Inc is focused on providing sustainable biocatalysis solutions to industries such as pharmaceuticals, food and beverage, and chemicals. Codexis employs proprietary protein engineering technology to create highly efficient biocatalysts that can replace traditional chemical processes, resulting in cost savings, increased product yields, and reduced environmental impact. By collaborating with its customers, Codexis develops customized enzymes and processes that address specific challenges and improve overall efficiency in various manufacturing processes. Codexis aims to offer value-added solutions to help its customers achieve their sustainability goals while maintaining profitability.
Codexis Inc is primarily active in the biotechnology industry.
The main competitors of Codexis Inc in the market include companies such as DSM, Ginkgo Bioworks, and Amyris.
Codexis Inc is a leading protein engineering company based in Redwood City, California. Founded in 2002, Codexis specializes in designing and optimizing enzymes for various industries, including pharmaceuticals, food and beverages, and sustainable chemistry. With a strong focus on biocatalysis, the company utilizes its proprietary CodeEvolver® platform to develop customized enzyme solutions that enhance the manufacturing processes of its clients. Over the years, Codexis has established itself as a key player in the biotech industry, collaborating with global partners and attracting numerous high-profile clients. By leveraging its expertise in directed evolution and protein engineering, Codexis continues to drive innovation and provide sustainable solutions to address complex challenges in different sectors. As a leader in the field, Codexis Inc consistently strives to deliver value and impact through the application of biocatalysis and its cutting-edge enzyme technologies.
Codexis Inc has achieved several significant milestones throughout its history. One notable achievement was the commercialization of its proprietary CodeEvolver® protein engineering platform. This innovation enabled the company to develop and optimize bio-based processes for various industries, including pharmaceuticals, food and beverages, and chemicals. Another milestone was when Codexis partnered with leading companies like Merck, GlaxoSmithKline, and Shell, showcasing its reputation as a trusted collaborator. Additionally, the company's successful initial public offering (IPO) in 2010 marked a major milestone, providing Codexis with the financial resources to further expand its cutting-edge biocatalysis technologies. Overall, Codexis Inc has consistently demonstrated industry leadership and achieved significant progress in advancing sustainable solutions.
Codexis Inc is primarily present in the United States.
Codexis Inc represents a strong commitment to innovation and sustainability in the biotechnology industry. The company's corporate philosophy is centered around delivering transformative solutions for its customers and creating value for its stakeholders. Codexis Inc is dedicated to leveraging its proprietary technologies and expertise to develop and commercialize high-performance enzymes and other bio-based products. By harnessing the power of biocatalysis, the company aims to enable more sustainable manufacturing processes across various sectors. Codexis Inc's steadfast dedication to excellence and its focus on delivering sustainable solutions makes it a prominent player in the biotechnology industry.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 5,00 USD för Codexis-aktien (median: 5,00 USD), vilket innebär +274,5 % mot senaste kurs. Konsensus baseras på 13 analytikerbetyg.
13 analytiker betygsätter för närvarande Codexis-aktien: 10 rekommenderar köp, 3 behåll och 0 sälj. För 2026 väntar sig analytiker att Codexis genererar intäkter på 73,89 M USD och vinst per aktie på −0,37 USD.
Omräknat till aktuell växelkurs handlas Codexis-aktien till 1,20 EUR (1,34 USD).
Codexis-aktien (CDXS) är noterad på 7 börser, bland annat: NASDAQ (CDXS), London (0I0X.L), SIX (Zürich) (4QK.SW), Frankfurt (4QK.F), München (4QK.MU), Düsseldorf (4QK.DU).
Codexis Inc. is a specialist in enzyme technology, operating since 2002 and based in Redwood City, California. The company's business model includes three main areas: enzyme development, proteins, and research services. By combining its capabilities in enzyme technology and protein engineering, Codexis has created unique solutions tailored to the needs of the biotechnology, chemical, pharmaceutical, and food industries. The core business of Codexis is enzyme development. Codexis manufactures enzymes that help customers improve chemical processes by exhibiting higher activities and selectivities, making the production of chemicals and bioproducts more cost-effective and environmentally friendly. The company has developed a range of enzymes used in industrial biotechnology, including medicines, seed treatments, food and feed additives, as well as detergents and cleaning agents. In addition to enzyme development, Codexis also offers proteins that the company uses for biochemical analysis, diagnostics, and protein production. Another business area of Codexis is the manufacturing of enzymes for use in IVD diagnostics. These enzymes are used in medicine and biotechnology, particularly in clinical diagnostics and quality assurance. Codexis also provides research services based on enzyme and protein engineering solutions. The company's research department specializes in developing high-performance enzymes and proteins that enable a variety of applications. Furthermore, Codexis utilizes its research capabilities to offer contract research services in protein engineering and expression, as well as enzyme screening and optimization. Codexis has also developed fluorescence spectroscopy technology that allows for the real-time measurement of enzyme activity. These advanced enzyme engineering tools are essential for customers looking to optimize their processes and improve cost-effectiveness. In terms of its business model, Codexis generates its revenues primarily through the sale of enzyme products and contract research services. The company also pursues licensing revenue for its technology related to the development and use of enzymes in the industry. The company is committed to maintaining and expanding its competitive position in the field of enzyme and protein engineering technology. Codexis continuously strives to develop promising technologies for its customers and strengthen its research and development in this area. By supporting its customers with its specific, customized solutions and continually investing in research and development, Codexis positions itself as a leading provider of enzyme and protein engineering technologies.
Omsättningen för förväntad Codexis är 73,89 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Codexis är −33,93 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Codexis är för närvarande −3,58. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Codexis-aktien.
Kurs-försäljningskvoten (P/S) för Codexis är för närvarande 1,64. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Codexis-aktien.
Eulerpool Quality Score för Codexis är 3/10.
ISIN för Codexis är US1920051067. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Codexis är A0Q2S4. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Codexis är CDXS. Tickersymbolen används för att handla Codexis-aktier på börsen.
Codexis aktie
Codexis Jämförbar grupp
Codexis Ticker
Codexis FIGI
Alla nyckeltal och djupgående analys av Codexis
Vår aktieanalys av Codexis-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Codexis. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: